Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21.1 million for Q3 2025, reflecting a 56% year-over-year growth, with a gross margin of 73.7% [1][5][6] - The company achieved a recurring revenue of $8.3 million in Q3 2025, marking a 55% increase year-over-year, which constitutes 40% of total revenue [1][5] - For the first nine months of 2025, Sofwave's revenue reached $58.7 million, a 42% year-over-year growth, with a gross margin of 75.1% [1][5][6] - Sofwave reported a net income of $1.4 million for the first nine months of 2025, a significant turnaround from a net loss of $3.8 million in the same period of the previous year [1][5][6] - The company has administered approximately 667,000 pulse treatments since commercialization and anticipates achieving net profitability by 2025 [1][8] Financial Highlights - Q3 2025 revenue was $21.1 million, up from $13.5 million in Q3 2024, with a gross profit of $15.5 million, a 53% increase year-over-year [5][6] - The first nine months of 2025 saw revenues of $58.7 million compared to $41.3 million in the same period of 2024, with a gross profit of $44.1 million, reflecting a 41% increase [5][6] - Positive cash flow of $2.5 million was generated in Q3 2025, compared to $0.2 million in the corresponding period of the previous year [5][6] Management Commentary - The CEO of Sofwave highlighted the exceptional performance in Q3 2025, driven by over 50% year-over-year growth in both capital equipment placements and recurring revenue, indicating strong demand from customers [4] - The Chairman emphasized the record revenue as a testament to the company's disruptive technology and the shift in the aesthetic market towards next-generation treatment solutions [4] - The company is positioned to expand further in the non-invasive medical aesthetics space, driven by the growing adoption of GLP-1 treatments [4]

Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21 million in Q2 2025, reflecting a 43% year-over-year growth, and expects to achieve operating break-even for the full year [3][4][5] - The company has a strong recurring revenue stream, with $9.2 million in Q2, representing a 53% year-over-year increase, and over 40% of total revenue coming from recurring sources [4][5][9] - Sofwave's innovative technology and FDA clearances are driving rapid adoption in the aesthetic medical device market, with over 600,000 treatments conducted since launch [3][8][9] Financial Highlights - Q2 2025 revenue reached $21 million, a 43% increase from $14.6 million in Q2 2024; gross profit was $15.9 million, up 42% year-over-year [4][5][7] - First half revenue totaled $37.7 million, a 35% increase year-over-year, with gross profit of $28.6 million, reflecting a 36% growth [5][7] - The company generated $3.6 million in cash during Q2 2025, with cash and cash equivalents amounting to $24 million as of June 30, 2025 [4][5] Operational Highlights - Sofwave's technology, SUPERB™, is FDA-cleared for various aesthetic treatments, including wrinkle reduction and muscle toning, enhancing its market position [8][9] - The company has seen significant growth in brand awareness, surpassing 1 million social media followers, which supports its market presence [3][4] - Sofwave's operational discipline and strong balance sheet are key factors in its ongoing growth strategy [3][9]